Biotechnology Companies Announce Presentations, Stock Options Update and Financial Results - Research Report on Gilead Sciences,

   Biotechnology Companies Announce Presentations, Stock Options Update and
   Financial Results - Research Report on Gilead Sciences, Alexion Pharma,
                  Aegerion Pharma, Vanda Pharma, and Tesaro

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 12, 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences Inc. (NASDAQ: GILD), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN),
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Vanda Pharmaceuticals, Inc.
(NASDAQ: VNDA), and Tesaro, Inc. (NASDAQ: TSRO). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On November 7, 2013, Gilead Sciences Inc. (Gilead Sciences) announced that 10
abstracts describing the Company's investigational agents for several
hematological malignancies have been selected for presentation at the Annual
Meeting of the American Society of Hematology (ASH), to be held from December
7, 2013 to December 10, 2013 in New Orleans. The Company informed that the
aforementioned abstracts describe clinical and pre-clinical data from studies
of idelalisib, which is currently under review by the US Food and Drug
Administration for treatment of refractory indolent non-Hodgkin's lymphoma
(iNHL), as well as for GS-9973, GS-9820 and momelotinib (formerly CYT387 /
GS-0387). The Full Research Report on Gilead Sciences Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Alexion Pharmaceuticals, Inc. Research Report

On November 7, 2013, Alexion Pharmaceuticals, Inc. (Alexion Pharmaceuticals)
announced that researchers will present data from clinical studies of Soliris
(eculizumab) for the treatment of patients with paroxysmal nocturnal
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two
life-threatening and ultra-rare diseases, at the 55th Annual Meeting of the
American Society of Hematology (ASH). According to the Company, Soliris is the
first and only approved treatment for PNH and aHUS. Alexion Pharmaceuticals
informed that the aforesaid annual meeting will be held from December 7, 2013
to December 10, 2013, at the Ernest N. Morial Convention Center in New
Orleans. The Full Research Report on Alexion Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4619_ALXN]

--

Aegerion Pharmaceuticals, Inc. Research Report 

On November 6, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that
it granted stock options to purchase an aggregate of 21,075 shares of common
stock to seven new employees under the inducement stock option program, on
November 1, 2013. According to the Company, each stock option has an exercise
price per share equal to $82.80, the closing price of Aegerion's common stock
on the grant date; vests 25% on the first anniversary of the date of grant
with the remaining 75% to vest in monthly installments over the three years
thereafter; has a ten year term; and is subject to the terms and conditions of
Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of
a stock option agreement covering the grant. The Full Research Report on
Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/a3f6_AEGR]

--

Vanda Pharmaceuticals, Inc. Research Report

On November 7, 2013, Vanda Pharmaceuticals, Inc. (Vanda Pharmaceuticals)
reported its financial results for Q3 2013. The Company's revenue increased
1.2% YoY to $25.1 million during the quarter. Net loss was $12.6 million or
$0.43 per diluted share in Q3 2013, compared to net loss of $21.3 million or
$0.75 per diluted share in Q3 2012. The Full Research Report on Vanda
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b5ad_VNDA]

--

Tesaro, Inc. Research Report

On November 7, 2013, Tesaro, Inc. (Tesaro) reported its financial results for
Q3 2013. Net loss was $13.6 million or $0.52 per diluted share in Q3 2013,
compared to net loss of $28.6 million or $0.88 per diluted share in Q3 2012.
Commenting on the results, CEO of Tesaro, Lonnie Moulder said, "We continued
to advance our late stage clinical pipeline during the third quarter. Two of
our Phase 3 trials of oral rolapitant are now fully enrolled, and we look
forward to announcing top-line data from these studies at year end, with
results from the third study becoming available in early 2014. Preparations
are underway for the submission of a New Drug Application for oral rolapitant
to the U.S. Food and Drug Administration in mid-2014. We are currently
screening patients for enrollment in the BRAVO study of niraparib, and are
very pleased with the level of interest we are receiving from investigators in
our ongoing NOVA trial." The Full Research Report on Tesaro, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4258_TSRO]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.